Aminoacetic Acid 1.5% In Plastic Container
(glycine)Phase 3Small molecule
OtsukaAminoacetic Acid 1.5% In Plastic Container is one of 126 small molecule programs targeting Malnutrition. It is currently in Phase 3.
5
Indications
12
Total Trials
0
Active Trials
125
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Aminoacetic Acid 1.5% In Plastic Container
OtsukaPhase 3
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Zocor
OOrganon and Co
Preclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Inversine
TTargacept Inc.
Preclinical
Permax
VValeant Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Schizophrenia4 trials
Malnutrition2 trials
Tic Disorder2 trials
2 more indications
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
NDA NDA017865
Jan 1, 1982
GLYCINE 1.5% IN PLASTIC CONTAINER
NDA NDA016784
Jan 1, 1982
GLYCINE 1.5% IN PLASTIC CONTAINER
NDA NDA017633
Jan 1, 1982
GLYCINE 1.5% IN PLASTIC CONTAINER
NDA NDA018315
Feb 19, 1982
GLYCINE 1.5% IN PLASTIC CONTAINER
NDA NDA018522
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for glycine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]